LIGAND PHARMACEUTICALS INCORPORATED Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) had Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One of $295.97 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost · last filed 2026-02-27
- 2025-12-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $295.97M.
- 2024-12-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $127.30M.
- 2023-12-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $55.36M.
- 2022-12-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $57.16M.
| Period end | Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2025-12-31 | $295.97M 10-K · filed 2026-02-27 |
| 2024-12-31 | $127.30M 10-K · filed 2025-02-28 |
| 2023-12-31 | $55.36M 10-K · filed 2024-02-29 |
| 2022-12-31 | $57.16M 10-K · filed 2023-02-28 |
| 2021-12-31 | $111.33M 10-K · filed 2022-02-28 |
| 2020-12-31 | $141.73M 10-K · filed 2021-02-24 |